Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 31, 2024
Product Development
Immunotherapies break into cold colorectal cancers at ASCO
Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer
BioCentury | Dec 19, 2023
Deals
Compugen gets badly-needed lift as Gilead strikes deal for IL-18 program
Stock gain could be enough to keep Israel-based biotech above delisting threshold
BioCentury | Nov 8, 2023
Deals
BioNTech looks to Biotheus again, this time for bispecific-ADC combo
German biotech’s second deal with Biotheus marks its fifth in-licensing agreement this year with a Chinese biotech
BioCentury | Jun 16, 2023
Deals
Surface accepts buyout; deal helps Coherus build innovative pipeline
Nine-year-old immuno-oncology company’s value had dwindled since deprioritizing CD47 program, entering GSK deal
BioCentury | Jun 1, 2023
Data Byte
The next-generation checkpoint pipeline expands, slowly
The majority of T cell checkpoint targets tracked by BioCentury continue to see new entrants to the pipeline
BioCentury | Jan 20, 2022
Product Development
Barron’s departure leaves unfinished business in GSK’s cancer pipeline
CSO stepping down to join biopharma ‘dream team’ at newly launched Altos
BioCentury | Jul 7, 2021
Management Tracks
In GSK’s Hoos, Scorpion gains oncology pathfinder to match its $270M war chest
Departure follows rebuild of pharma’s cancer pipeline
BioCentury | Jun 14, 2021
Deals
GSK fuels TIGIT frenzy with $625M payout for iTeos’ mAb
iTeos’ Phase I anti-TIGIT mAb draws one of the largest-ever immuno-oncology deals
BioCentury | Mar 26, 2021
Product Development
Next-generation checkpoint development surges as rare wins overshadow setbacks
Companies look to overcome challenges in next-generation checkpoints with new targets and modalities
BioCentury | Dec 18, 2020
Product Development
Next-generation checkpoints acting on NK and T cells: Data Byte
Following the early success of anti-TIGIT mAbs in clinical development this year, interest in next-generation checkpoints has been on the rise, and there’s reason to believe that checkpoints
Items per page:
1 - 10 of 17